Aurelie Lagrange
Overview
Explore the profile of Aurelie Lagrange including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mourlanette J, Rousseau-Bussac G, Mallah S, Guisier F, Zalcman G, Veillon R, et al.
Target Oncol
. 2025 Mar;
PMID: 40080277
Background: ROS1 chromosomic rearrangement is a rare oncogenic driver, and patients with this rearrangement benefit from specific targeted treatments in the first-line setting. However, therapeutic options are limited in pretreated...
2.
Roussot N, Thibaudin M, Fumet J, Daumoine S, Hampe L, Rebe C, et al.
Front Immunol
. 2024 Aug;
15:1437961.
PMID: 39170614
A patient with a PD-L1-negative, TMB-low, co-mutated metastatic non-small cell lung cancer (NSCLC) experienced a multisite radiological progression at 3 months after initiation of chemoimmunotherapy as first-line treatment for metastatic...
3.
Dalens L, Niogret J, Richard C, Chevrier S, Foucher P, Coudert B, et al.
Mol Cancer
. 2023 Jul;
22(1):120.
PMID: 37516818
Background: Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free survival...
4.
Dalens L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108755
Immune checkpoint inhibitors (ICIs) have improved the care of patients in multiple cancer types. However, PD-L1 status, high Tumor Mutational Burden (TMB), and mismatch repair deficiency are the only validated...
5.
Adotevi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, et al.
J Clin Oncol
. 2022 Sep;
41(2):373-384.
PMID: 36070539
Purpose: Universal cancer peptide-based vaccine (UCPVax) is a therapeutic vaccine composed of two highly selected helper peptides to induce CD4+ T helper-1 response directed against telomerase. This phase Ib/IIa trial...
6.
Tankere P, Boidot R, Bonniaud P, Zouak A, Foucher P, Milliere A, et al.
J Thorac Dis
. 2022 Jul;
14(6):2034-2044.
PMID: 35813741
Background: The best management for rare epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung carcinoma (NSCLC) remains uncertain. The literature indicates that response to usual treatment could...
7.
Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35277462
Background: Endogenous retroviruses (ERVs) are highly expressed in various cancer types and are associated with increased innate immune response and better efficacy of antiprogrammed death-1/ligand-1 (anti-PD1/PD-L1)-directed immune checkpoint inhibitors (ICI)...
8.
Tankere P, Zanetta S, Kaderbhai C, Bellio H, Lagrange A, Garcier M, et al.
Am J Case Rep
. 2022 Mar;
23:e934980.
PMID: 35232952
BACKGROUND Small cell carcinoma (SCC) is usually aggressive and associated with a poor prognosis. This type of cancer is rarely found in extra-pulmonary or digestive-tract locations. This report describes an...
9.
Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, et al.
Eur J Cancer
. 2022 Feb;
165:13-24.
PMID: 35189537
Background: Patients with cancer are a population at high risk of severe infection from SARS-CoV-2. Patients with cancer regularly attend specialised healthcare centres for management and treatment, where they are...
10.
Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, et al.
Cancer Cell
. 2022 Jan;
40(2):136-152.e12.
PMID: 35051357
Chemotherapy with anti PD-1/PD-L1 antibodies has become the standard of care for patients with metastatic non-small cell lung cancer (mNSCLC). Using lung tumor models, where pemetrexed and cisplatin (PEM/CDDP) chemotherapy...